Shareen Doak is Professor of Genotoxicology and Cancer in Swansea University Medical School. Shareen is the Medical School’s Director of the Centre for NanoHealth and she leads the In Vitro Toxicology Group. Shareen is a UK and EUROTOX Registered Toxicologist, an invited Fellow of the Royal Society of Biology (FRSB) and an elected Fellow of the Learned Society of Wales (FLSW).

Shareen sits on the UK Government Committee on Mutagenicity (COM), and is the Nanomaterials Working Group Co-Leader for the International Genetic Toxicology Technical Committee (GTTC). She is also Senior Editor for Mutagenesis.

Shareen Coordinates the €13Million H2020 PATROLS project ( and is Director of the €12Million Celtic Advanced Life Science Innovation Network (CALIN), an Ireland-Wales INTERREG operation established to build a innovation bridge between Wales and Ireland in life sciences.

Shareen’s research interests focus on the genotoxic profiles of engineered nanomaterials, the mechanisms underlying their DNA damaging potential and subsequent consequences upon human health. Her interests extend to the development of advanced 3D culture models and mechanism-based bioassays for safety assessment to reduce the need for animal testing. Her prostate cancer research focuses on understanding the molecular basis of progression to invasive, aggressive disease; with an ultimate aim of identifying a prognostic biomarker panel for improved clinical management of patients.